The positive preclinical seizure data de-risks CMP-002's therapeutic profile and supports the upcoming Phase 1/2 trial initiation in 2H 2026. Monitor for IND filing and trial enrollment updates as key catalysts. The updated corporate slide presentation (Exhibit 99.2) may contain additional pipeline or financial details worth reviewing.
Price Chart
Executive Summary
CAMP4 Therapeutics presented new preclinical data for CMP-002, its lead ASO candidate for SYNGAP1-related disorder, at the TIDES conference. The data showed statistically significant improvement in seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. The company expects to advance CMP-002 into a Phase 1/2 clinical trial in the second half of 2026.
Key Facts
- CMP-002 produced a statistically significant improvement in both seizure threshold and severity of chemically-induced tonic-clonic seizures in SYNGAP1 haploinsufficient mice.
- CAMP4 expects to advance CMP-002 into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in the second half of 2026.
- SYNGAP1-related disorder affects over 10,000 individuals in the United States with no approved disease-modifying therapies.
- The filing is a Regulation FD disclosure (Item 7.01) of a press release and updated corporate slide presentation.
Financial Impact
No financial data provided in the filing.
Risk Factors
- Preclinical results may not translate to human clinical outcomes.
- Clinical-stage biotech with no approved products or revenue; high cash burn risk.
- Phase 1/2 trial initiation in 2H 2026 is subject to regulatory and operational delays.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001736730-26-000033 |
| Document: a20260514exhibit991.htm | 0001736730-26-000033 |
| Document: 0001736730-26-000033-index-headers.html | 0001736730-26-000033 |
| Document: 0001736730-26-000033-index.html | 0001736730-26-000033 |
| Document: 0001736730-26-000033.txt | 0001736730-26-000033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $4.34 $4.03 | ▼ −7.14% | ▼ −6.64% | $3.73 (−13.95%) |
Sep 2, 2026 29d ago | Insider Cluster | $4.49 $4.25 | ▼ −5.35% | ▼ −4.20% | $3.73 (−16.83%) |
Aug 21, 2026 6w ago | Insider Cluster | $4.48 $4.15 | ▲ +7.37% | ▲ +7.84% | $3.73 (+16.64%) |
Aug 13, 2026 7w ago | EFFECT | $4.50 $4.45 | ▼ −1.11% | ▲ +0.85% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Jul 27, 2026 9w ago | 8-K | $3.42 $3.45 | ▲ +0.88% | ▼ −0.20% | $3.73 (+9.20%) |
Jun 19, 2026 14w ago | Press Release | $4.20 $4.20 | · 0.00% | ▲ +2.07% | $3.73 (−11.08%) |
Jun 12, 2026 15w ago | 8-K | $3.96 $4.20 | ▲ +6.06% | ▲ +7.44% | $3.73 (−5.69%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.22 $4.14 | ▼ −1.90% | ▼ −2.33% | $3.73 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access